Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

In-silico Immunomodelling of 2019-nCoV

View through CrossRef
Abstract Background: Novel Corona Virus 2019 (2019-nCoV) is a positive-sense single-strand RNA virus form coronaviridae family, responsible for corona virus infectious disease 2019 (COVID-19) with rapid transmission. The aim of this study is characterization of major viral proteins, prediction of antigen proteasomal cleavage pattern, MHC class I processing and presentation, B- and T-cell epitopes, and anti-inflammatory epitopes of 2019-nCoV, compared with SARS-CoV. Methods: The aminoacid sequence of spike surface (S) glycoprotein, membrane (M) glycoprotein, envelop (E) protein and nucleocapsid (N) phosphoprotein were obtained from NCBI. The sequences were aligned by MEGA 7.0 and modeled by SWISS-MODEL. The proteasomal cleavage pattern, MHC class I processing and T-cells epitopes were predicted via IEDB analysis and EPISOFT. The B-cell epitopes were predicted by BepiPred 2.0. Also, prediction of anti-inflammatory epitopes was performed by AntiFlam. Results: Two major antigen proteins, S glycoprotein and M glycoprotein of 2019-nCoV, respectively, have 26.57% and 20.59% less efficiency in proteasomal cleavage and presentation to MHC class I, comparing SARS-CoV. There are less B-cell predicted epitopes in 2019-nCoV, comparing SARS-CoV. The anti-inflammatory properties of 2019-nCoV S glycoprotein and N protein is higher than SARS-CoV. Discussion: It seems that the evolution of 2019-nCoV is on the way of deficiency in antigen presenting to MHC class I and escaping from cellular immunity. Also, the predicted hotspot epitopes potentially can be used to induction of adaptive cellular immunity against 2019-nCoV. In addition, 2019-nCoV appears to be less immunopathogenic than SARS-CoV due to its higher anti-inflammatory proteins.
Title: In-silico Immunomodelling of 2019-nCoV
Description:
Abstract Background: Novel Corona Virus 2019 (2019-nCoV) is a positive-sense single-strand RNA virus form coronaviridae family, responsible for corona virus infectious disease 2019 (COVID-19) with rapid transmission.
The aim of this study is characterization of major viral proteins, prediction of antigen proteasomal cleavage pattern, MHC class I processing and presentation, B- and T-cell epitopes, and anti-inflammatory epitopes of 2019-nCoV, compared with SARS-CoV.
Methods: The aminoacid sequence of spike surface (S) glycoprotein, membrane (M) glycoprotein, envelop (E) protein and nucleocapsid (N) phosphoprotein were obtained from NCBI.
The sequences were aligned by MEGA 7.
0 and modeled by SWISS-MODEL.
The proteasomal cleavage pattern, MHC class I processing and T-cells epitopes were predicted via IEDB analysis and EPISOFT.
The B-cell epitopes were predicted by BepiPred 2.
Also, prediction of anti-inflammatory epitopes was performed by AntiFlam.
Results: Two major antigen proteins, S glycoprotein and M glycoprotein of 2019-nCoV, respectively, have 26.
57% and 20.
59% less efficiency in proteasomal cleavage and presentation to MHC class I, comparing SARS-CoV.
There are less B-cell predicted epitopes in 2019-nCoV, comparing SARS-CoV.
The anti-inflammatory properties of 2019-nCoV S glycoprotein and N protein is higher than SARS-CoV.
Discussion: It seems that the evolution of 2019-nCoV is on the way of deficiency in antigen presenting to MHC class I and escaping from cellular immunity.
Also, the predicted hotspot epitopes potentially can be used to induction of adaptive cellular immunity against 2019-nCoV.
In addition, 2019-nCoV appears to be less immunopathogenic than SARS-CoV due to its higher anti-inflammatory proteins.

Related Results

Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2
Abstract The burgeoning epidemic caused by novel coronavirus 2019 (2019-nCoV) is currently a global concern. Angiotensin-converting enzyme-2 (ACE...
In silico identification of vaccine targets for 2019-nCoV
In silico identification of vaccine targets for 2019-nCoV
Background: The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it ...
Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Purpose: As of from 30 Jan to 31 May, 2020, more than 182,143 confirmed cases reported in India along with 86,984 recovered cases and 5164 deceased cases of COVID-19. More than 53 ...
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
Safety and Immunogenicity of a Booster SARS-Cov-2 Vaccination in Patients with Chronic Liver Disease
ABSTRACT This article is aim to investigate the safety and immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster in pat...
Assessment of Community Psycho-behavioral Responses during the outbreak of novel coronavirus (2019-nCoV): A cross sectional study
Assessment of Community Psycho-behavioral Responses during the outbreak of novel coronavirus (2019-nCoV): A cross sectional study
Abstract Background: The novel coronavirus 2019 (2019-nCoV) is a public health emergency of international concern resulting in adverse psychological impacts during the epid...
Retrospective Analysis of 2019-nCov-Infected Cases in Dongyang, Southeastern China
Retrospective Analysis of 2019-nCov-Infected Cases in Dongyang, Southeastern China
The 2019 novel coronavirus (2019-nCov) has caused increasing number of infected cases globally. This study was performed to analyze information regarding the transmission route and...

Back to Top